Barcelona-based Gate2Brain secures €7 million to advance brain tumour candidate (opens in new tab)

Barcelona-based Gate2Brain, a promising BioTech company, has secured €7 million in its largest investment round to date. This significant funding will advance their therapeutic candidate for aggressive brain tumours, signalling continued investor confidence in European oncology innovation. The strategic partnership with Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited, further bolsters Gate2Brain's mission to tackle critical unmet medical needs.The investment positions Gate2Bra...